Key facts: Eli Lilly Q3 revenues soar 53.9% to $17.6B; weight-loss drug launch planned
I'm PortAI, I can summarize articles.
Eli Lilly's Q3 revenues hit $17.6 billion, up 53.9% year-on-year, exceeding forecasts by 9.7%. The stock rose 32.7% since the report, now trading at $1,077.1Eli Lilly plans to launch an oral weight-loss drug, orforglipron, pending regulatory approval. The pill will be priced at $149 for starters and $399 for repeat buyers.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments